Cargando…

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro

Detalles Bibliográficos
Autores principales:	Amrein, Lilian, Panasci, Lawrence, Gibson, Spencer B, Johnston, James B, Soulières, Denis, Aloyz, Raquel
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2009
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774145/ https://www.ncbi.nlm.nih.gov/pubmed/19758122 http://dx.doi.org/10.1111/j.1365-2141.2009.07814.x

Ejemplares similares

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
por: Davidson, David, et al.
Publicado: (2013)

Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming
por: Marignac, Veronica Martinez, et al.
Publicado: (2013)

Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Comment on: “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Papamichos, Spyros I., et al.
Publicado: (2020)

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

Expert consensus on the management of chronic lymphocytic leukaemia in Asia
por: Tse, Eric, et al.
Publicado: (2023)

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
por: Abu-Sanad, Atlal, et al.
Publicado: (2015)

Pharmacological targeting of eIF4E in primary CLL lymphocytes
por: Martinez-Marignac, V, et al.
Publicado: (2013)

Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12
por: McCaig, Alison M., et al.
Publicado: (2012)

The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells
por: Hofbauer, Sebastian W., et al.
Publicado: (2015)

DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
por: Kost, Sara E. F., et al.
Publicado: (2023)

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms
por: Hutterer, Evelyn, et al.
Publicado: (2015)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

The t(11;14)(q13;q32)/CCND1–IGH translocation in chronic lymphocytic leukaemia/small lymphocytic lymphoma: an unusual genetic aberration during the natural clinical course
por: Liu, Ying, et al.
Publicado: (2019)

In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia
por: Giannopoulos, Krzysztof, et al.
Publicado: (2021)

UGT2B17 modifies drug response in chronic lymphocytic leukaemia
por: Allain, Eric P., et al.
Publicado: (2020)

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor
por: Wierda, William G., et al.
Publicado: (2018)

A Case of Lymphocytic Leukæmia
por: Reynolds, Fredrick H.
Publicado: (1933)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

Bruton’s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes
por: Sharif-Askari, Bahram, et al.
Publicado: (2019)

Molecular characterization and clonal evolution in Richter transformation: Insights from a case of plasmablastic lymphoma (RT‐PBL) arising from chronic lymphocytic leukaemia (CLL) and review of the literature
por: Ramsey, Megan C., et al.
Publicado: (2023)

Telomerase Contributes to Fludarabine Resistance in Primary Human Leukemic Lymphocytes
por: Shawi, May, et al.
Publicado: (2013)

Seasonality in the diagnosis of acute lymphocytic leukaemia.
por: Badrinath, P., et al.
Publicado: (1997)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

The Uptake and Utilization of Chlorambucil by Lymphocytes from Patients with Chronic Lymphocytic Leukaemia
por: Hill, Bridget T., et al.
Publicado: (1972)

Lymphocytic lymphoma/B-chronic lymphocytic leukaemia--an immunohistopathological study of peripheral B lymphocyte neoplasia.
por: Swerdlow, S. H., et al.
Publicado: (1984)

THE DEVELOPMENT OF HYPERSENSITIVE LYMPHOCYTES IN CELL CULTURE
por: Ginsburg, Haim, et al.
Publicado: (1971)

Development of expression-based biomarkers of Dasatinib response in hematologic malignancies
por: Akre, Monica K., et al.
Publicado: (2017)

Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib
por: Blätte, Tamara J., et al.
Publicado: (2020)

Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance.
por: Williamson, K. E., et al.
Publicado: (1998)

THE LYMPHOCYTIC ORIGIN OF A PLASMA FACTOR RESPONSIBLE FOR HYPERSENSITIVITY IN VITRO OF TUBERCULIN TYPE
por: Miller, Joseph M., et al.
Publicado: (1951)

Ribosomal RNA Synthesis in Chronic Lymphocytic Leukaemia
por: Billington, R. W., et al.
Publicado: (1974)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin B
por: Yoon, J-Y, et al.
Publicado: (2013)

A case of leukaemia cutis in a dog with T‐cell chronic lymphocytic leukaemia
por: Bae, Hyeona, et al.
Publicado: (2022)

Vancomycin Hypersensitivity Diagnosed by Lymphocyte Blast Transformation
por: Tran, Nguyen P., et al.
Publicado: (2011)

Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study
por: Beiggi, S, et al.
Publicado: (2013)

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
por: Takahashi, Naoto, et al.
Publicado: (2012)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells
por: Holmes, Katie B., et al.
Publicado: (2019)

The inhibition of DNA synthesis in chronic lymphocytic leukaemia cells by chlorambucil in vitro.
por: Bentley, D. P., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_ct4o7ot9dssphss0282i0i647v